AstraZeneca Results Presentation Deck

2021 guidance updated Alexion is now included Total revenue increase by a low- twenties percentage Core EPS faster growth to $5.05 to $5.40 Based on 1,418 million weighted average number of shares in issue during 2021 The guidance does not incorporate any revenue or profit impact from sales of the pandemic COVID-19 vaccine. In general, AstraZeneca continues to recognise the heightened risks and uncertainties from the effects of COVID-19, including the impact from potential new medicines for COVID-19 in clinical development. Variations in performance between quarters can be expected to continue. 25 B

View entire presentation